Is Ionis Pharmaceuticals a Buy?
In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Brian Orelli discuss the potential of Ionis Pharmaceuticals' (NASDAQ: IONS) antisense platform, which has already resulted in a few drug launches. The company is working to lower the level of specific RNAs, which can ultimately turn off a gene that's potentiating a disease. The simplicity of Ionis' antisense platform has helped the biotech create a broad pipeline of drugs.
Source Fool.com
